A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
NCT ID: NCT01884974
Last Updated: 2015-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research:
1. Assess Prevalence of PH in patients with CMPD in Northern Israel
2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardio Pulmonary Exercise Testing in Patients Post the Fontan Palliation in Comparison With Patients With Repaired Congenital Heart Disease and Healthy Volunteers.
NCT02659462
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction
NCT01191879
Characterization of Slow Coronary Flow
NCT02025101
Effect of Medical Treatment on Longitudinal Function of the Heart
NCT02237794
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients
NCT00716898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* sex
* age
* BMI
* ethnicity
* age diagnosed with Myeloproliferative disease
* clinical manifestations of the myeloproliferative disease
* JAK2 mutation
* known hematological complications
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
myeloproliferative disease
Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
myeloproliferative disease
Echocardiogram, demographic data, St George respiratory questioner
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
myeloproliferative disease
Echocardiogram, demographic data, St George respiratory questioner
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carmel Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shoshan Perek
Dr Shoshan Perek
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shoshan Perek, MD
Role: PRINCIPAL_INVESTIGATOR
Carmel Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pulmonology Institute, Carmel Medical Center
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shoshan Perek, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMC-12-0060-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.